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Background: The adipokine visfatin exerts 
proinflammatory effects in synovial fibroblasts 
of patients having rheumatoid arthritis. 
Results: Visfatin induces high amounts of 
chemokines creating a microenvironment of 
enhanced fibroblast motility. 
Conclusion: Visfatin is therefore very capable of 
contributing to the inflammatory state in 
rheumatoid arthritis. 
Significance: Enlightening visfatin 
pathophysiology may lead to possible 
therapeutic targeting in the future. 
SUMMARY 
Adipokines such as adiponectin or 
visfatin/pre-B cell colony enhancing factor 
(PBEF) have been recently shown to 
contribute to the synovial inflammation in 
rheumatoid arthritis (RA). In the present 
study, we evaluated the pathophysiological 
implication of visfatin/PBEF in the molecular 
patterns of RA synovial tissue focusing on 
synovial fibroblasts (SFs), key players in RA 
synovium. Expression of visfatin/PBEF in 
synovial fluid and tissue of RA patients was 
detected by immunoassays and 
immunohistochemistry. RASFs were 
stimulated  with  different  concentrations   of
       
visfatin/PBEF over varying time intervals and 
changes in gene expression were evaluated on 
RNA and protein level using Affymetrix 
array, real-time PCR and immunoassays. 
Involved signaling pathways were identified. 
Influence of visfatin/PBEF on fibroblast 
motility and migration was analyzed. In RA 
synovium, visfatin/PBEF was predominantly 
expressed in the lining layer, lymphoid 
aggregates and interstitial vessels. In RASFs, 
visfatin/PBEF induced high amounts of 
chemokines such as interleukin-8 (IL-8) and 
monocyte chemotactic protein-1 (MCP-1), 
proinflammatory cytokines such as IL-6 as 
well as matrix-metalloproteinases like MMP-
3. Phosphorylation of p38 mitogen-activated 
protein kinase (MAPK) was observed after 
visfatin/PBEF stimulation and inhibition of 
p38MAPK showed strong reduction of 
visfatin-induced effects. Directed as well as 
general fibroblast motility was increased by 
visfatin/PBEF-induced factors. The results of 
the study indicate that visfatin/PBEF is 
involved in the synovial fibroblast activation 
by triggering fibroblast motility and 
promoting cytokine synthesis at central sites 
in RA synovium. 
 
 http://www.jbc.org/cgi/doi/10.1074/jbc.M111.312884The latest version is at 
JBC Papers in Press. Published on July 5, 2012 as Manuscript M111.312884
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INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic 
polyarticular disease manifesting as painful 
inflammation of the synovial tissues and 
progressive destruction of the joints. Besides 
macrophages, T- and B-cells, synovial 
fibroblasts (SFs) as resident cells are key players 
in mediating most of the relevant pathways in 
this process (1, 2). Activation of RASFs in the 
synovium results in the production of 
proinflammatory cytokines and matrix-metallo-
proteinases (MMPs). RASFs actively perpetuate 
inflammation as well as matrix degradation and 
invasion leading to progressive destruction of the 
articular cartilage and the adjacent bone, thus 
determining the outcome of the disease (1, 3, 4). 
The terms adipocytokines or adipokines are used 
for cytokine-like molecules synthesized by 
adipocytes, e.g. including adiponectin, leptin, 
resistin and visfatin. There is growing evidence 
that adipose tissue is not only a repository for 
triglycerides or a passive connective tissue, but 
in fact an active endocrine organ regulating 
energy homeostasis and metabolism (5). 
Moreover, adipose tissue and obesity are 
connected with a low-grade state of 
inflammation and play a role in other chronic 
inflammatory disorders including RA (6, 7).  
The expression of the adipokine pre-B-cell-
colony-enhancing factor (PBEF) in plasma, 
synovial fluid as well as in the inflamed 
synovium of RA patients is elevated (8-11). In 
experimental settings like antigen-induced 
arthritis in mice similar results could be seen (8). 
Thus far, it has been shown that during 
activation of immune cells such as macrophages, 
monocytes, dendritic cells, neutrophils and T- 
and B-cells, visfatin/PBEF expression is 
increased (12-17). In turn, it has been reported 
that visfatin/PBEF up-regulates IL- -1ra, IL-
6, IL-10 and TNF-  in PBMCs and IL-1 , IL-6 
and TNF-  in CD14
+ 
monocytes (12). It is 
known that visfatin/PBEF induces different 
intracellular signaling pathways, e.g. AP-1 and 
NF- B in RASFs (9). In CD14
+
 monocytes, the 
visfatin/PBEF-induced cytokine production 
could be reduced by inhibiting p38MAPK- and 
MEK1-pathways (12). Given the fact, that 
visfatin/PBEF acts additionally as the rate-
limiting enzyme in the salvage pathway of NAD, 
recycling NAD from nicotinamide, it prevents 
neutrophil apoptosis in experimental 
inflammation and clinical sepsis and promotes 
vascular smooth muscle cell maturation thus 
extending their lifespan (13, 18, 19). 
Visfatin/PBEF was originally described as a 
cytokine involved in early B-cell development  
and was later renamed visfatin due to the fact 
that it is mainly secreted by visceral fat (20, 21) 
Recent studies showed that visfatin/PBEF is up-
regulated in activated RASFs under 
inflammatory stimuli such as STAT-3-dependent 
IL-6 trans-signaling on the one hand and on the 
other by poly(I-C)-mediated TLR-3 activation 
(8, 9). In turn, visfatin/PBEF induces IL-6 in 
RASFs suggesting a positive feedback 
mechanism due to proinflammatory activities of 
this protein (9). 
In our study, we investigated the effects of 
visfatin/PBEF on RASFs in detail with the main 
focus specifically on the change in gene and 
protein expression mediated by visfatin/PBEF, 
signaling pathways involved in those processes 
and alterations in fibroblast motility in order to 
further clarify the role of visfatin/PBEF in RA.  
 
EXPERIMENTAL PROCEDURES 
Tissue specimens and cell culture 
During routine synovectomy synovial tissue was 
obtained from patients with RA and 
osteoarthritis (OA). Patients met the 1987 
criteria of the American College of 
Rheumatology (ACR) classifying RA and OA 
(22, 23). RASFs were cultured as described 
recently (24-26). Synovial fluid of RA patients 
with articular effusion was aspirated. Primary 
human lymphocytes were isolated with Ficoll-
gradient centrifugation from buffy coat samples 
of healthy donors. Primary human lymphocytes 
were cultured in RPMI 1640 (PAA Laboratories) 
supplemented with 5% human serum (PAA 
Laboratories), 100 U/ml penicillin, 10 µg/ml 
streptomycin and 10 mM HEPES (PAA 
Laboratories) at 37°C and 5% CO2.  
Stimulation assays 
Recombinant human visfatin/PBEF (100ng/ml, 
subsequently mentioned as visfatin/PBEF, 
Biovendor) was used throughout the experiments 
if not mentioned otherwise. To exclude effects of 
stimulation-related cell division, cell counting 
was performed. 
Dose-effect relationship 
RASFs were stimulated with increasing 
concentrations of visfatin/PBEF (2.5-, 5-, 10-, 
50-, 100-, 250-, 500-, 2500-, 5000-, 
10000ng/ml). Unstimulated RASF served as 
control, whereas stimulation with adiponectin 
(25µg/ml, R&D Systems) served as positive 
control (27). IL-6 and -8 served as parameters. 
Time-dependent response 
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RASFs were stimulated with visfatin/PBEF for 
4h up to 48h. IL-6 and -8 production was 
quantified over time.  
Affymetrix GeneChip  expression analysis 
RASFs were stimulated with 500ng/ml 
visfatin/PBEF for 15h. RNA was extracted using 
the RNeasy™ MiniPrep Kit (Qiagen). Target 
preparation and hybridization for the Affymetrix 
human genome U133 Plus 2.0 GeneChip   
(AFFX) was performed according to the 
protocol. Results of the two condition design 
were analyzed with the GeneSpring microarray 
analysis software (Silicon Genetics) to obtain 
Increase/Decrease or No Change calls.   
Real-time PCR  
RNA was isolated using the RNeasy™ Mini Kit 
(Qiagen). Reverse transcription was performed 
using AMV Reverse Transcriptase (Promega) 
and random hexamer primers (Roche). Primers 
(listed in Supplemental data 1) were designed 
and efficiency for each primer pair was tested 
using standard curve method (E=10
-1/slope
) 
considering 2.00 0.05 acceptable for 
experiments. Real-time PCR was performed 
using LightCycler  (Roche) with SYBR Green I 
(Roche) as detection system. Melting curve 
analysis was used to confirm specificity of 
amplification. 18S RNA served as reference 
gene. Results were analyzed using Roche 
LightCycler  software.   
Western Blot analysis of p38 phosphorylation 
Cell extracts were harvested in NETN buffer 
(0.5% NP-40, 1mM EDTA, 20mM Tris-HCl at 
pH 8.0, 100mM NaCl and 10% glycerol) 
containing 1x complete protease inhibitor 
cocktail (Roche). Protein was separated on a 
SDS 10% (w/v) polyacrylamide gel and blotted 
onto nitrocellulose membrane (BioRad). Proteins 
were detected by antibodies against 
phosphorylated and total p38 (Cell Signalling 
Technology). Detection was performed by 
horseradish peroxidase-conjugated secondary 
antibodies (Dako) and an enhanced 
chemiluminescence detection kit (ECL
+
 Western 
Blotting Detection System, GE Healthcare). All 
western blots were probed for Cyclophilin B 
(Abcam) to ensure equal loading of samples.  
Enzyme immunoassay (EIA) and enzyme-
linked immunosorbent assay (ELISA) 
Commercially available ELISAs and EIAs 
(R&D Systems; Phoenix Europe) were 
performed in accordance with the protocol. 
Absorption was measured at 450nm and data 
were analyzed using Magellan software (Tecan). 
Inhibition of signal transduction pathways  
Cultured RASFs were preincubated for 1.5h with 
chemical inhibitors of signal transduction 
pathways: 1) p38MAPK-inhibitor SB203580 
(20µM; Sigma-Aldrich), 2) cell-permeable 
myristoylated protein kinase C (PKC) inhibitor 
20-28 (40µM; Calbiochem) 3) cell-permeable 
myristoylated protein kinase A (PKA) inhibitor 
14-22 (2µM; Calbiochem), 4) cell-permeable 
NF- B activation inhibitor (40µM; Calbiochem). 
Subsequent to the preincubation, cells were 
stimulated with visfatin/PBEF for 6 and 15h in 
presence of inhibitors. Stimulation of RASFs 
with visfatin/PBEF served as positive control, 
unstimulated RASFs with or without inhibitors 
as negative control.  
Immunohistochemistry 
Snap frozen RA and OA synovial tissues 
sections were prepared. Nonspecific binding was 
blocked with 2% bovine serum albumin followed 
by overnight incubation in a moist chamber at 
4°C with rabbit anti-human visfatin antibodies 
(10µg/ml; Bethyl Laboratories (9)). Endogenous 
peroxidase activity was blocked with 0.3% H2O2 
in 100% methanol. Sections were then incubated 
with Histofine Simple Stain MAX PO (multi) 
anti-mouse/-rabbit (Nichirei Biosciences) for 30 
minutes. Color development with AEC-substrate 
(Vector Laboratories) at room temperature was 
stopped after microscopic examination followed 
by counterstaining of the nuclei using 
hematoxylin. Rabbit isotype-matched IgG sera 
(Santa Cruz Biotechnology) served as isotype 
control, mouse anti-human vimentin (Dako) as 
positive control. Negative control without 
primary antibody was carried out.  
Chemotaxis 
Migration of RASFs was measured using a 48-
well Boyden microchemotaxis chamber 
(Neuroprobe). Conditioned medium was 
prepared incubating RASFs for 16h in DMEM 
without FCS. In contrast, stimulated media were 
acquired by stimulation for 16h with: 1. 
visfatin/PBEF (100ng/ml), 2. visfatin/PBEF and 
p38MAPK inhibitor (100ng/ml; 20µM) and 3. 
p38MAPK inhibitor (20µM); all in DMEM 
without FCS. Besides using different cell 
populations, experimental replicates were also 
performed. 
20,000 cells in 50µl conditioned medium were 
placed in the upper chamber. In the lower 
chamber, 30µl of conditioned medium 
(migration baseline), medium with 10% FCS and 
without FCS (positive and negative controls, 
respectively) and stimulated media (as 
mentioned above) were added. Both chambers 
were separated by an 8µm pore-size filter (GE 
Osmonics). After migration for 7h, cells on the 
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upper filter side were scraped off. Filters were 
fixed and stained. Of each well, 6 areas were 
photographed, amount of cells was counted, and 
data were expressed as migration index (ratio of 
sample to baseline, (28)).  
Migration of lymphocytes was measured using a 
24-well Transwell
®
 migration assay (Corning). A 
total of 10
6
cells was added onto the filter. Into 
the lower well the prepared conditioned medium 
and stimulated media (as described above) were 
placed. In the control experiment, we tested 
visfatin/PBEF diluted in normal DMEM and 
10% FCS. Cells were allowed to migrate for 4h 
at 37°C. Cells in the lower well were enumerated 
with a haemocytometer.  
Scrape motility assay 
RASFs were preincubated with increasing 
concentrations of visfatin/PBEF (5-, 25-, 50-, 
100-, 250ng/ml) for 1.5h. Beginning from the 
centre of each well, cells were removed by 
scraping using a 100µl pipette tip. To visualize 
cell motility within the scrape line, photos of the 
defined, cell-free scraped areas were taken every 
1.5 hours between 8 to 17h after scraping (29). 
Cells migrating into the gap were counted and 
data were expressed as comparison of sample to 
baseline in percentages. Besides using different 
cell populations, experimental replicates were 
performed as well. 
Statistics 
Statistical analysis was performed using Student 
t test. Arithmetic means and standard errors of 
the mean (SEM) were calculated. Issues were 
regarded as significant for p<0.05 (*), p<0.01 
(**) and p<0.001 (***). Statistical evaluation 
was performed using GraphPad Prism 5. 
 
RESULTS 
Detection of Visfatin/PBEF in RA synovial 
fluid and synovium 
The mean concentration of visfatin/PBEF in RA 
synovial fluid was 76.26±7.22ng/ml (n=24; 
Figure 1A). A strong expression of 
visfatin/PBEF in RA synovium (n=3), mainly in 
the synovial lining layer, in lymphoid aggregates 
and perivascular areas could be observed 
indicating contribution to the inflammation of 
the synovium by local visfatin/PBEF production 
independent of adipose tissue. Visfatin/PBEF 
protein was expressed in OA synovium (n=2) as 
well but to a lesser extent and mainly in regions 
of interstitial vessels (Figure 1B).  
Identification and confirmation of genes 
regulated by visfatin/PBEF in RASFs 
To elucidate the effects of visfatin/PBEF on 
RASFs in a broad approach, the changes in gene 
expression and protein production were analyzed 
using AFFX (n=1) as screening method, and 
real-time PCR (n=7-9) and ELISA (n=4-5) for 
confirmation. Of note, the fold induction was 
different as expected between the non-
quantitative AFFX in comparison to the 
quantitative techniques real-time PCR and 
ELISA as well as due to the different stimulation 
concentrations (500ng/ml versus 100ng/ml). 
Several genes were strongly altered by 
visfatin/PBEF (Table 1). Amongst them, 
chemokines of the CXC- and CC-families were 
predominantly represented and showed the 
highest fold changes. Chemokines (CXCL-1, -2, 
-3, -5, -6, -8 and CCL-2, -5, -13, -20) were 
therefore quantified on RNA as well as on 
protein level and their regulation could be 
confirmed in each case (see Table 1). 
Verification of the observed regulation was also 
performed on the protein level for IL-6 and 
MMP-3. In addition, several cytokines including 
interleukin-1 , -6, -7, -8, -15, -32, -33, 
interleukin 1 receptor antagonist, as well as the 
adipokines adiponectin and PBEF itself were 
induced in the AFFX (see Supplemental data 2). 
A variety of key factors in RA pathophysiology 
were not regulated on protein level in RASFs by 
visfatin/PBEF: pro-MMP-1, activin A, OPG, 
IGFBP-2, -3, TIMP-1, -2 (n=3-4; Supplemental 
data 3). IL-1  and TNF-  levels were below the 
detection level (data not shown). 
Establishment of dose-dependent 
relationships and time-dependent responses 
for visfatin/PBEF stimulation of RASFs 
With regard to the variability of visfatin/PBEF 
concentrations in synovial fluids of RA patients, 
we determined whether the concentration of 
visfatin/PBEF plays a critical role in the 
production of proinflammatory markers like IL-6 
and IL-8. We further investigated whether the 
incubation period of RASFs with visfatin/PBEF 
leads to an additional increase or suppression of 
cytokine production over time.  
Dose-dependent relationships 
The effect of visfatin/PBEF on IL-6 and IL-8 
production of RASFs was dose-dependent. Basal 
concentration of IL-6 was 23.3pg/10³cells, which 
was increased up to 477.96pg/10³cells by 
visfatin/PBEF stimulation (100ng/ml). IL-8 was 
increased from 0.72pg/10³cells up to 
199.49pg/10
3
cells (Figure 2A). For subsequent 
stimulation experiments 100ng/ml visfatin/PBEF 
was used, which was located in the linearly 
increasing section of the curve and showed a 
significant effect on the production of 
proinflammatory cytokines. Further increase of 
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visfatin/PBEF concentration did not result in an 
additional increase in cytokine production and 
lead to a plateau in the dose-dependency curve 
(Figure 2A). 
Time-dependent responses 
After stimulating RASFs for 15h with 
visfatin/PBEF (100ng/ml), the basal 
concentration of IL-6 was increased from 
14.9pg/10
3
cells up to 106.04pg/10
3
cells. For IL-
8, the basal concentration was increased from 
3.97pg/10
3
cells up to 67.42pg/10
3
cells. 
Extending the incubation period up to 48h 
resulted in reduction of cytokine production 
maybe due to counterregulation (Figure 2B). 
However, 15h of incubation were used 
throughout the stimulation experiments to avoid 
secondary regulatory mechanisms taking place 
after longer incubation periods in vitro. 
Signaling pathways involved in 
visfatin/PBEF-mediated production of IL-6 
and CCL-2 
Inhibition of the intracellular pathways of 
p38MAPK (12, 30), NF- B (9), PKA (31) and 
PKC (32, 33) in RASFs was performed to 
observe whether the induction of 
proinflammatory cytokines (i.e. IL-6) and 
chemokines (i.e. CCL-2) by visfatin/PBEF 
depend on them.  
IL-6 
Incubation with the inhibitor of the p38MAPK 
pathway resulted in strong reduction of 
visfatin/PBEF-mediated IL-6 production in 
RASFs. IL-6 production was reduced from 
439.3±103.09pg/10³cells to 
150.4±50.31pg/10³cells (reduction of 66%; 
p=0.033; n=3; Figure 3A) after 15h and from 
88.16±22.17pg/10³cells to 24.47±5.29pg/10³cells 
(reduction of 72%; p=0.087; n=3; Figure 3B) 
after 6h compared to visfatin/PBEF-stimulated 
RASFs without p38MAPK inhibitor. Other 
inhibitors (PKC inhibitor 20-28, PKA inhibitor 
14-22, NK- B activation inhibitor) had no 
influence on IL-6 production (Supplemental data 
4).  
CCL-2 
None of the inhibiting factors significantly 
reduced visfatin/PBEF-mediated CCL-2 
production in RASFs in contrast to IL-6 
production (Supplemental data 4). 
p38 MAPK 
Furthermore, we observed a clearly elevated 
basal phosphorylation of p38 in RASF as 
exposure to visfatin/PBEF (100ng/ml) for 5 
minutes strongly activated the p38-signaling 
cascade (Figure 3C). 
Visfatin/PBEF influences synovial fibroblast 
and lymphocyte motility 
Next, we analyzed whether the induction of pro-
inflammatory factors and chemokines induced in 
RASFs via visfatin/PBEF leads to a cytokine 
environment of increased directed (chemotaxis 
assay) and/or general (scrape assay) cell motility 
of RASFs and/or lymphocytes. 
Scrape assay 
The aim was to determine whether increasing 
concentrations of visfatin/PBEF induce cell 
motility not directed towards a chemokine 
gradient. The contribution of cell proliferation to 
the repopulation of the scraped zone was 
minimized using serum-free media. The findings 
demonstrated augmented cell motility for 
concentrations of visfatin/PBEF of 5, 25 and 
50ng/ml (n=3; Figure 4B-D). The strongest 
increase in motility was found for visfatin/PBEF 
at 25 ng/ml (+13.3±2.7%, p=0.038 and 
+18.4±3.6, p=0.035 compared to baseline after 8 
and 15.5h; Figure 4C). No significant change in 
fibroblast motility was discovered for 
visfatin/PBEF at 100 and 250ng/ml (data not 
shown). The effects were evened out at the latest 
time points due to completely filling in the 
scraped gap. Interestingly, visfatin/PBEF at 
100ng/ml, the concentration used for the 
chemotaxis experiments, showed almost no 
altered general cell motility. 
Chemotaxis assay 
Stimulation of RASFs with visfatin/PBEF led to 
increased amounts of chemokines (Table 1). 
Migration towards these media could be detected 
analyzing RASFs and lymphocytes. The 
migration index for RASFs was 2.73±0.45 (n=2; 
Figure 5A). Supplementary experiments showed 
that migration to visfatin/PBEF-stimulated media 
could nearly be reduced to baseline (1.08±0.59; 
n=2; 60% reduction) if preincubated with the 
p38MAPK inhibitor. The p38MAPK inhibitor 
itself reduced to some extent the migratory 
potential of RASFs (0.39±0.31; n=2; Figure 5A). 
Simultaneous to the effects of visfatin/PBEF-
induced factors on RASFs, lymphocyte 
migration was increased, but could be reduced 
via p38MAPK inhibition (n=2; Figure 5B). To 
see, whether increased migration is indeed 
caused by visfatin/PBEF-induced factors and not 
by visfatin/PBEF itself, we measured 
lymphocyte migration towards media containing 
100ng/ml visfatin/PBEF and found no significant 
change in migration (n=2; Figure 5C).  
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DISCUSSION 
In the present study, we investigated the 
potential of visfatin/PBEF to act as an effector 
molecule in RA. The significant changes in gene 
expression of RASFs mediated by 
visfatin/PBEF, especially the induction of a 
variety of chemokines and moreover 
proinflammatory and matrix-degrading factors, 
could be confirmed on RNA and protein level. 
This supports the hypothesis that visfatin/PBEF 
creates an inflammatory molecular environment 
of increased fibroblast and leukocyte motility 
within RA synovial tissue. 
Inflammation of the synovium is a hallmark in 
RA and activated RASFs play a central role in 
local pathophysiological mechanisms. In the 
inflamed synovium of RA patients accumulation 
of visfatin/PBEF was most dominant at the site 
of cartilage invasion (9), in the lining layer, in 
lymphoid aggregates and around interstitial 
vessels, confirming that fibroblasts, lymphocytes 
and endothelial cells are expressing 
visfatin/PBEF in the synovial tissue and that are 
exposed to increased concentrations of 
visfatin/PBEF in return (8, 20, 34). 
The lining layer contains high numbers of 
activated RASFs characterized by a high basal 
production of IL-6 and MMPs advancing chronic 
inflammatory responses, contributing to T-cell 
and B-cell activation and progressive cartilage 
destruction (35). Visfatin/PBEF enhances these 
effects by increasing the production of IL-6 and 
MMP-3, -10, -12 and -19. Therefore, 
visfatin/PBEF intensifies the aggressive 
phenotype of RASFs. This holds also true for 
visfatin-mediated stimulation of chondrocytes, 
resulting in higher amounts of prostaglandin E2 
and MMP-3, and CD
+
 14 monocytes, expressing 
higher amounts of IL-6, IL-1  and TNF- , as 
recently reported (12, 36). By elucidating the 
change in gene expression of RASFs after 
visfatin/PBEF stimulation, we could show that a 
broad variety of chemokines of both, the CXC- 
and the CC-cluster, are strongly up-regulated 
suggesting that visfatin/PBEF mediates 
chemoattraction in RA synovium to a significant 
extent. In addition, visfatin/PBEF elevates the 
expression of adhesion molecules like VCAM-1, 
ICAM-1 and -2 enabling RASFs to increased 
attachment to cartilage but also to contribute to 
cell migration (1). Chemoattraction is mediated 
via enhanced cell motility. Our results support 
the idea that visfatin/PBEF operates as an cell 
motility increasing molecule for RASFs in vitro 
in a similar way as it was shown for CD14
+
 
monocytes and CD19
+
 B cells under other 
pathophysiological conditions (12). The 
visfatin/PBEF-induced cytokine-environment 
exerts chemoattractive properties promoting 
directed fibroblast motility to the site of 
visfatin/PBEF expression. Furthermore, the 
visfatin/PBEF-induced cytokine-environment 
contributes to lymphocyte recruitment. 
Therefore, visfatin/PBEF may contribute to 
accumulation of RASFs in the lining layer as 
well as at sites of cartilage invasion (1, 37) 
resulting in increased matrix-destruction and -
remodeling at the invasion zone, a characteristic 
of hyperplastic RA synovium. 
The inflammatory process in RA synovium is 
also driven by the influx of inflammatory cells 
into the synovial tissue and activated interstitial 
vessels play a key role in the extravasation of 
leukocytes. Increased expression of 
visfatin/PBEF around interstitial vessels and a 
strong induction of IL-8, VEGF and ECGF, 
factors with strong pro-angiogenic effect (38, 
39), was observed. It is likely that visfatin/PBEF 
promotes also RA synovial angiogenesis to some 
extent. This process has been demonstrated for 
visfatin/PBEF-mediated activation of ERK-1/-2 
pathways as well as for increase of FGF-2 in 
human endothelial cells (40-43). 
Due to the fact that IL-6 and MMP-1 production 
is closely linked to PKC and p38MAPK 
activation (30-32, 44-46) and that initiation of 
common pathways such as PKA and NF- B 
result in inflammatory responses of RASFs (30, 
33), we investigated whether the observed effects 
were mediated via those pathways. Although it 
was shown that visfatin/PBEF activates the NF-
B pathway in RASFs (9), the only significant 
effects we could detect were seen by inhibition 
of the p38MAPK pathway. Of interest, 
p38MAPK inhibition in animal models of 
arthritis leads to improvement of the disease 
severity, thus reflecting its central role in arthritis 
(47, 48). 
Taken together, the results of the study show that 
visfatin/PBEF is a strong effector molecule in 
the pathophysiology of RA, specifically by 
contributing to the production of 
proinflammatory chemokines in RASFs, matrix-
degrading enzymes and proangiogenic 
molecules. The data also support the idea that the 
effects of adipokines are not restricted to adipose 
tissue but are operative in chronic inflammatory 
joint diseases. 
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FIGURE LEGENDS 
 
FIGURE 1. Detection of visfatin/PBEF in RA synovial fluid and synovium. A, Mean concentration of 
visfatin/PBEF in the synovial fluid of RA patients (n=24; age: 66.1±16 years; 83.3% female) 
measured by ELISA. B, Nuclei-counterstained immunohistochemical analysis for visfatin/PBEF 
protein in RA (n=3) and OA synovium (n=2). Visfatin/PBEF protein shows red, nuclei blue 
(magnification x400). In RA synovium, SFs in the lining layer showed a strong expression of 
visfatin/PBEF (black arrow). Small interstitial vessels (black arrowhead) and lymphoid aggregates 
(white arrow) express visfatin/PBEF protein as well. In OA synovium, minor vessels of the 
interstitium show visfatin/PBEF protein expression (white arrowhead). Isotype control using OA 
synovium was performed. ss, synovial space; ll, lining layer; sl, sublining; v, vessel; la, lymphoid 
aggregate; i, interstitium. 
 
FIGURE 2. Dose-dependent relationship and time-dependent response after visfatin/PBEF 
stimulation of RASFs. A, Top line. RASFs were incubated for 15h with increasing concentrations of 
visfatin/PBEF (presented range 2.5 to 2500 ng/ml). IL-6 and IL-8 production was measured by 
ELISA. Data is expressed as concentration of cytokine (pg/10³cells) to stimulation concentrations of 
visfatin/PBEF. B, Bottom line. RASFs were stimulated with 100 ng/ml visfatin/PBEF for 4 up to 48 
hours. IL-6 and IL-8 production was measured by ELISA. Data is presented as concentration of 
cytokine (pg/10³cells) to stimulation time. Dotted lines display the stimulation concentration and time 
chosen for subsequent experiments. 
 
FIGURE 3. Involvement of the p38 MAPK pathways in visfatin/PBEF-mediated production of IL-6 
in RASFs using an intracellular signaling inhibitor. RASFs (n=3) were stimulated with or without 
visfatin/PBEF (100 ng/ml) together with and without the chemical inhibitor of p38MAPK. Values are 
expressed as arithmetic means ± SEM. A, after 15 hours. B, after 6 hours. C, Basal and visfatin/PBEF 
induced activation of phospho-p38 in RASF. * p<0.05. 
 
FIGURE 4. Visfatin/PBEF influences synovial fibroblast motility. A, Scrape assay pictures represent 
the difference in cell motility over time between cell culture wells of the negative control and wells of 
the sample (visfatin/PBEF 25ng/ml). Pictures from the start of the experiment and after 8 hours and 
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15.5 hours are displayed. Scrape assays were performed as described in methods (n=3). Results were 
expressed as comparison of samples to baseline (percentages). The graphs show enhanced cell motility 
in the samples after 8h and 15.5h for B, 5 ng/ml; C, 25 ng/ml; D, 50 ng/ml. * p<0.05. 
 
FIGURE 5. Visfatin/PBEF influences synovial fibroblast motility. A, RASF chemotaxis assays were 
performed (see methods) and migration index was calculated (baseline set to 1, ratio of sample to 
baseline). Means ± SEM are displayed as bars (n=2). B, Demonstrating lymphocyte migration to 
conditioned media of RASF (n=2, total number of migrated lymphocytes are shown), results are 
expressed as means ± SEM (see methods). C, Incubation with 100 ng/ml visfatin/PBEF had only a 
slight effect on lymphocyte migration (n=2, fold increase of migration is shown). 
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TABLES 
Table 1 Change in the gene expression of RASFs after stimulation with visfatin/PBEF: Selection of 
genes regulated by visfatin/PBEF 
Gene Name 
Gene 
Symbol 
Fold Change 
AFFX 
Fold Change 
Real-Time 
Fold Change 
ELISA 
Chemokines 
chemokine (C-C motif) ligand 20 (CCL20) MIP-3  1024.00  28.97±11.5 
chemokine (C-C motif) ligand 5 (CCL5) RANTES 473.71  30.56±13.79 
chemokine (C-X-C motif) ligand 8 (CXCL8) IL-8 164.03  51.29±13.79* 
chemokine (C-X-C motif) ligand 1 (CXCL-1) GRO-  90.51 17.21±4.69** 18.28±8.05 
chemokine (C-X-C motif) ligand 3 (CXCL3) GRO-  51.98 14.77±2.82**  
chemokine (C-X-C motif) ligand 5 (CXCL5) ENA-78 22.63 14.32±2.79** 6.39±1.22* 
chemokine (C-X-C motif) ligand 6 (CXCL6) GCP-2 18.38 114.82±35.6* 12.88±3.26* 
chemokine (C-X-C motif) ligand 2 (CXCL2) GRO-  17.96 10.95±2.72**  
chemokine (C-C motif) ligand 13 (CCL13) MCP-4 13.93 6.96±1.49**  
chemokine (C-C motif) ligand 2 (CCL2) MCP-1 13.93 4.83±1.37* 3.29±0.95 
Cytokines      
interleukin 6 IL6 10.56  6.07±0.94* 
Proteinases & Peptidases      
matrix metallopeptidase 3 MMP3 59.71  3.63±0.77* 
matrix metallopeptidase 1 MMP1 16.00  1.19±0.14 
Data are presented as mean value ± standard error of the mean; * = <0.05; ** = <0.01 
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FIGURE 1 
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FIGURE 2 
 
 
 at H
auptbibliothek U
niversitaet Zuerich Irchel. Bereich Forschung on M
arch 10, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
PBEF, a proinflammatory, cell-motility changing factor in RA 
13 
 
FIGURE 3 
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FIGURE 4 
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FIGURE 5 
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